Latest Inhaler Stories

Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

2013-05-22 04:21:01

OXFORD, England, May 22, 2013 /PRNewswire/ -- First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, has initiated a Phase 2 clinical study with PSX1002 that will assess its effect on...

Boehringer Ingelheim Presents Phase 3 Sub-Analyses for Tiotropium Across a Range of Symptomatic Asthma Patients at ATS 2013

2013-05-21 08:29:37

Boehringer Ingelheim also presents new data from a Phase 2 study demonstrating increased bronchodilation with 5 mcg tiotropium as an add-on therapy in symptomatic patients with moderate persistent asthma at the American Thoracic Society International Conference (ATS 2013) RIDGEFIELD, Conn., May 21, 2013 /PRNewswire/ -- Boehringer Ingelheim today announced data from Phase 2 and Phase 3 studies from the Company's ongoing clinical trial program investigating the efficacy and safety of...

Asthmapolis CEO to Present at Respiratory Drug Delivery (RDD®) Europe 2013

2013-05-20 08:25:53

MADISON, Wis., May 20, 2013 /PRNewswire/ -- Asthmapolis (az-MAP-o-lis), the FDA-cleared mobile health solution for asthma and COPD, today announced CEO David Van Sickle will give an invited presentation during Respiratory Drug Delivery (RDD(®)) Europe 2013 in Berlin, Germany. On Friday, May 24 at 8:30 a.m., Van Sickle will present "Monitoring and Improving Compliance and Asthma Control: Mapping Inhaler Use for Feedback to Patients, Physicians and Payers" as part of the session track,...

Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference

2013-05-17 08:23:49

Data on investigational compounds and an approved product will be presented RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- Boehringer Ingelheim will contribute to advancing the scientific discussion in respiratory disease at the American Thoracic Society International Conference (ATS 2013) in Philadelphia, PA, May 17 - 22.( )Data will highlight research conducted with a product approved for the treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler®...

Transition to Propellant-Free Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray Nears Completion

2013-05-17 08:23:25

Combivent® Respimat® (ipratropium bromide and albuterol) Inhalation Spray will become the only available short-acting bronchodilator offering two different medicines in a single inhaler RIDGEFIELD, Conn., May 17, 2013 /PRNewswire/ -- As part of the company's commitment to chronic obstructive pulmonary disease (COPD) patients, Boehringer Ingelheim Pharmaceuticals, Inc., a leader in respiratory health, is updating healthcare professionals (HCPs) and patients that the transition to...

North America Leads the Drug Delivery Technology Market Followed by Europe & Asia Pacific - New Report by MarketsandMarkets

2013-05-02 23:22:13

[316 Pages Report] Drug Delivery Technology Market Report categorizes the Global Market by Metered Dose Inhalers, Auto Injectors, Transdermal Patches, Drug Eluting Stentscand Infusion Pumps Forecasting - 2017. (PRWEB) May 02, 2013 The "Drug Delivery Technology Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017,"...

North America Leads Drug Delivery Technologies Market Followed by Europe Says New Research Report at ReportsnReports.com

2013-04-22 23:01:39

“Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017” is the new market research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) April 23, 2013 The drug delivery technology market is segmented on the basis of route of administration into nine categories - oral, pulmonary,...

Drug Delivery Technology Market worth $224.2 Billion By 2017

2013-04-22 04:21:12

DALLAS, April 22, 2013 /PRNewswire/ -- The "Drug Delivery Technology Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Global Forecasts To 2017", analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World. Browse - 118 market data tables - 29...

Study Published in PLOS ONE Highlights Improved Asthma Control and Fewer Symptoms After Using Asthmapolis System

2013-03-05 12:29:00

MADISON, Wis., March 5, 2013 /PRNewswire/ -- Asthmapolis today announced an investigation featuring the system in the remote monitoring of inhaled bronchodilator use and weekly feedback about asthma management has been published in the latest issue of the scientific journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0055335). The study found improved asthma control and a decline in day-to-day asthma symptoms for participants receiving Asthmapolis' weekly email reports and...

Asthmapolis Wins Bluetooth Breakthrough Product Award

2013-02-26 08:29:54

MADISON, Wis., Feb. 26, 2013 /PRNewswire/ -- Asthmapolis today announced the company won the inaugural Bluetooth® Breakthrough Award in the Product Category from the Bluetooth Special Interest Group (SIG). The SIG received over 300 submissions from around the world, and presented the awards during a special ceremony yesterday at Mobile World Congress in Barcelona, Spain. (Photo: http://photos.prnewswire.com/prnh/20130226/CG66068) "The Asthmapolis inhaler sensor and mobile...